The sequential use of immune-modulating medications to treat multiple sclerosis (MS), an inflammatory disease that affects the brain and spinal cord, triggered atypical hemolytic uremic syndrome (aHUS) in a 48-year-old woman, according to a case study. This case highlights “the importance of continuous clinical and laboratory monitoring in…
Discussion
A woman with atypical hemolytic uremic syndrome (aHUS) developed severe complications affecting the kidneys, brain, and heart, but recovered without lasting neurological damage after prompt treatment that included the complement blocker Soliris (eculizumab), a study showed. The complement cascade is a part of the immune system that is…
Becoming educated and informed about aHUS is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnist’s words of wisdom to help you along on your aHUS journey.
There is no cure for aHUS yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
